| Outcome Measures: |
Primary: PK: Amisulpride plasma exposure (AUC) after a single IV dose, Amisulpride plasma exposure after a single IV dose measured as the area under the concentration-time curve (AUC) between study drug administration and the time at which the following-day oral dose of Amisulpride is given, 24 hours | Secondary: PK: Amisulpride plasma exposure (AUC) after a single oral dose, Amisulpride plasma exposure after a single oral dose measured as the area under the concentration-time curve (AUC) from study drug administration extrapolated to infinity, 24 hours|PK: Cmax, Peak plasma concentration (Cmax), for both a single IV and single oral dose., 24 hours|PK: Tmax, Time at which peak plasma concentration achieved (Tmax) for both a single IV and single oral dose., 24 hours|PK: T1/2, Half-life (T1⁄2) of both a single IV and single oral dose., 24 hours|PK: Clearance, Clearance of both a single IV and single oral dose., 24 hours|PK: Vd, Volume of distribution (Vd) of both a single IV and single oral dose., 24 hours|Safety: AE, Frequency and severity of treatment-emergent adverse events, From first study drug administration until discharge (4 days)
|
